Table 3.

Results of renal biopsy in nondiabetic nephropathy^⁎

Pathology	Total (n=65)	A	B	C	D	E
MN	15 (23.1)	8 (53.3)	5 (33.3)	0 (0)	1 (6.7)	1 (6.7)
IgA nephropathy	14 (21.5)	6 (42.9)	3 (21.4)	3 (21.4)	2 (14.3)	0 (0)
ATIN	10 (15.4)	4 (40.0)	1 (10.0)	4 (40.0)	1 (10.0)	0 (0)
FSGS	6 (9.2)	3 (50.0)	1 (16.7)	2 (33.3)	0 (0)	0 (0)
MCD	5 (7.7)	1 (20.0)	2 (40.0)	1 (20.0)	1 (20.0)	0 (0)
HSP nephritis	4 (6.2)	2 (50.0)	0 (0)	1 (25.0)	1 (25.0)	0 (0)
DPGN	3 (4.6)	1 (33.3)	1 (33.3)	0 (0)	1 (33.3)	0 (0)
MesPGN	2 (3.1)	1 (50.0)	0 (0)	0 (0)	1 (50.0)	0 (0)
ANCA-GN	2 (3.1)	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)
HT nephropathy	2 (3.1)	0 (0)	0 (0)	1 (50.0)	1 (50.0)	0 (0)
MPGN	1 (1.5)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)
IgM nephropathy	1 (1.5)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)

Data are presented as n (%).

ATIN, acute tubulointerstitial nephritis; DPGN, diffuse proliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; HSP, Henoch–Schönlein purpura; HT, hypertensive; MCD, minimal change disorder; MesPGN, mesangial proliferative glomerulonephritis; MN, membranous nephropathy; MPGN, membranous proliferative glomerulonephritis.

^⁎A, Nephrotic range proteinuria (>3 g/day) with atypical course; B, Proteinuria without diabetic retinopathy [urine total protein (TP)>500 mg/day or spot urine TP/Cr>500 mg/g]; C, Unexplained decline of renal function; D, Unexplained hematuria (>3 red blood cells/high-power field); E, Proteinuria with short duration of diabetes (24 h urine TP>500 mg or spot urine TP/creatinine >500 mg/g within 5 years of diabetes).